These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 14695041)

  • 61. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
    Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
    Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
    [TBL] [Abstract][Full Text] [Related]  

  • 62. N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials.
    Stenstrom DA; Muldoon LL; Armijo-Medina H; Watnick S; Doolittle ND; Kaufman JA; Peterson DR; Bubalo J; Neuwelt EA
    J Vasc Interv Radiol; 2008 Mar; 19(3):309-18. PubMed ID: 18295688
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Acetylcysteine for prevention of contrast nephropathy: meta-analysis.
    Birck R; Krzossok S; Markowetz F; Schnülle P; van der Woude FJ; Braun C
    Lancet; 2003 Aug; 362(9384):598-603. PubMed ID: 12944058
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?
    Tanaka A; Suzuki Y; Suzuki N; Hirai T; Yasuda N; Miki K; Fujita M; Tanaka T
    Intern Med; 2011; 50(7):673-7. PubMed ID: 21467697
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In search of an algorithm to prevent acute kidney injury.
    Dauerman HL
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1125-7. PubMed ID: 19926055
    [No Abstract]   [Full Text] [Related]  

  • 67. The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients.
    Mathur VS
    Rev Cardiovasc Med; 2003; 4 Suppl 1():S35-40. PubMed ID: 12556736
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity.
    Sandhu C; Belli AM; Oliveira DB
    Cardiovasc Intervent Radiol; 2006; 29(3):344-7. PubMed ID: 16502177
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Strategies to reduce the risk of contrast nephropathy: an evidence-based approach.
    Pannu N; Tonelli M
    Curr Opin Nephrol Hypertens; 2006 May; 15(3):285-90. PubMed ID: 16609296
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review.
    Cruz DN; Perazella MA; Bellomo R; Corradi V; de Cal M; Kuang D; Ocampo C; Nalesso F; Ronco C
    Am J Kidney Dis; 2006 Sep; 48(3):361-71. PubMed ID: 16931209
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention.
    Kini AA; Sharma SK
    Rev Cardiovasc Med; 2001; 2 Suppl 1():S19-25. PubMed ID: 12439364
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Contrast-induced nephropathy.
    Pucelikova T; Dangas G; Mehran R
    Catheter Cardiovasc Interv; 2008 Jan; 71(1):62-72. PubMed ID: 17975790
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Does N-acetylcysteine prevent contrast-induced nephropathy?
    Vaitkus PT
    Am J Cardiol; 2002 Dec; 90(12):1424; author reply 1424-5. PubMed ID: 12480065
    [No Abstract]   [Full Text] [Related]  

  • 74. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interactions between serum creatinine, volume status, N-acetylcysteine, and contrast-induced nephropathy.
    Toprak O
    Ren Fail; 2006; 28(3):265-6. PubMed ID: 16703801
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Iodinated contrast agent-induced nephropathy].
    Erley C
    Radiologe; 2007 Sep; 47(9):761-7. PubMed ID: 17823784
    [TBL] [Abstract][Full Text] [Related]  

  • 77. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevention of radiocontrast-induced nephropathy.
    Asif A; Epstein M
    Am J Kidney Dis; 2004 Jul; 44(1):12-24. PubMed ID: 15211433
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures.
    Mintz EP; Gruberg L
    Expert Opin Pharmacother; 2003 May; 4(5):639-52. PubMed ID: 12739990
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients.
    Madyoon H
    Rev Cardiovasc Med; 2001; 2 Suppl 1():S26-30. PubMed ID: 12439365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.